Cargando…

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection

Detalles Bibliográficos
Autores principales:	Lan, Qiaoshuai, Pu, Jing, Cai, Yanxing, Zhou, Jie, Wang, Lijue, Jiao, Fanke, Xu, Wei, Wang, Qian, Xia, Shuai, Lu, Lu, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Institut Pasteur. Published by Elsevier Masson SAS. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133820/ https://www.ncbi.nlm.nih.gov/pubmed/34022374 http://dx.doi.org/10.1016/j.micinf.2021.104840

Ejemplares similares

25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
por: Lan, Qiaoshuai, et al.
Publicado: (2022)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
por: Xia, Shuai, et al.
Publicado: (2021)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
por: Xia, Shuai, et al.
Publicado: (2021)

A dePEGylated Lipopeptide-Based Pan-Coronavirus Fusion Inhibitor Exhibits Potent and Broad-Spectrum Anti-HIV-1 Activity without Eliciting Anti-PEG Antibodies
por: Xu, Ling, et al.
Publicado: (2023)

A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life
por: Duan, Qianyu, et al.
Publicado: (2022)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Pan-coronavirus fusion inhibitors as the hope for today and tomorrow
por: Wang, Xinling, et al.
Publicado: (2021)

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
por: Cai, Yanxing, et al.
Publicado: (2021)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability
por: Xue, Songyi, et al.
Publicado: (2023)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

Development of oncolytic virotherapy: from genetic modification to combination therapy
por: Lan, Qiaoshuai, et al.
Publicado: (2020)

Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors
por: Curreli, Francesca, et al.
Publicado: (2023)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19
por: He, Lin, et al.
Publicado: (2023)

IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies
por: Su, Xiaojie, et al.
Publicado: (2023)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein
por: Xue, Songyi, et al.
Publicado: (2022)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
por: Zhang, Hongwei, et al.
Publicado: (2016)

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants
por: Pu, Jing, et al.
Publicado: (2022)

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
por: Wang, Xinling, et al.
Publicado: (2020)

De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery
por: Wang, Chao, et al.
Publicado: (2018)

The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses
por: Xu, Wei, et al.
Publicado: (2018)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
por: Chong, Huihui, et al.
Publicado: (2019)

Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure
por: Chao, Lijun, et al.
Publicado: (2013)

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile
por: Xu, Wei, et al.
Publicado: (2022)

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
por: Lin, Yuxi, et al.
Publicado: (2021)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains
por: Xia, Shuai, et al.
Publicado: (2018)

Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates
por: Mathieu, Cyrille, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kg8bjba0rds5g3dtklhlojgpd4